TY - JOUR
T1 - TBVAC2020
T2 - Advancing tuberculosis vaccines from discovery to clinical development
AU - TBVAC2020 Consortium
AU - Kaufmann, Stefan H.E.
AU - Dockrell, Hazel M.
AU - Drager, Nick
AU - Ho, Mei Mei
AU - McShane, Helen
AU - Neyrolles, Olivier
AU - Ottenhoff, Tom H.M.
AU - Patel, Brij
AU - Roordink, Danielle
AU - Spertini, François
AU - Stenger, Steffen
AU - Thole, Jelle
AU - Verreck, Frank A.W.
AU - Williams, Ann
AU - Britton, Warwick
AU - Triccas, Jamie
AU - Counoupas, Claudio
AU - Grooten, Johan
AU - Marie-Ange Demoitie, Demoitie
AU - Romano, Marta
AU - Huygen, Kris
AU - Tima, Hermann Giresse
AU - Mascart, Francoise
AU - Andersen, Peter
AU - Aagaard, Claus
AU - Christensen, Dennis
AU - Ruhwald, Morten
AU - Lindenstrom, Thomas
AU - Charneau, Pierre
AU - Guilhot, Christophe
AU - Peixoto, Antonio
AU - Gilleron, Martine
AU - Vergne, Isabelle
AU - Locht, Camille
AU - Brosch, Roland
AU - Inchauspe, Genevieve
AU - Theung Long, Stephane Leung
AU - Weiner, January
AU - Maertzdorf, Jeroen
AU - Nieuwenhuizen, Natalie
AU - Bastian, Max
AU - Kallert, Stephanie
AU - Gordon, Stephen
AU - Caccamo, Nadia
AU - Goletti, Delia
AU - Nisini, Roberto
AU - Shin, Sung Jae
AU - Cho, Sang Nae
AU - Lee, Hyejon
AU - Choi, Ino
N1 - Publisher Copyright:
© 2017 Kaufmann, Dockrell, Drager, Ho, McShane, Neyrolles, Ottenhoff, Patel, Roordink, Spertini, Stenger, Thole, Verreck, Williams and TBVAC2020 Consortium.
PY - 2017/10/4
Y1 - 2017/10/4
N2 - TBVAC2020 is a research project supported by the Horizon 2020 program of the European Commission (EC). It aims at the discovery and development of novel tuberculosis (TB) vaccines from preclinical research projects to early clinical assessment. The project builds on previous collaborations from 1998 onwards funded through the EC framework programs FP5, FP6, and FP7. It has succeeded in attracting new partners from outstanding laboratories from all over the world, now totaling 40 institutions. Next to the development of novel vaccines, TB biomarker development is also considered an important asset to facilitate rational vaccine selection and development. In addition, TBVAC2020 offers portfolio management that provides selection criteria for entry, gating, and priority settings of novel vaccines at an early developmental stage. The TBVAC2020 consortium coordinated by TBVI facilitates collaboration and early data sharing between partners with the common aim of working toward the development of an effective TB vaccine. Close links with funders and other consortia with shared interests further contribute to this goal.
AB - TBVAC2020 is a research project supported by the Horizon 2020 program of the European Commission (EC). It aims at the discovery and development of novel tuberculosis (TB) vaccines from preclinical research projects to early clinical assessment. The project builds on previous collaborations from 1998 onwards funded through the EC framework programs FP5, FP6, and FP7. It has succeeded in attracting new partners from outstanding laboratories from all over the world, now totaling 40 institutions. Next to the development of novel vaccines, TB biomarker development is also considered an important asset to facilitate rational vaccine selection and development. In addition, TBVAC2020 offers portfolio management that provides selection criteria for entry, gating, and priority settings of novel vaccines at an early developmental stage. The TBVAC2020 consortium coordinated by TBVI facilitates collaboration and early data sharing between partners with the common aim of working toward the development of an effective TB vaccine. Close links with funders and other consortia with shared interests further contribute to this goal.
UR - http://www.scopus.com/inward/record.url?scp=85030571215&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85030571215&partnerID=8YFLogxK
U2 - 10.3389/fimmu.2017.01203
DO - 10.3389/fimmu.2017.01203
M3 - Review article
AN - SCOPUS:85030571215
SN - 1664-3224
VL - 8
JO - Frontiers in Immunology
JF - Frontiers in Immunology
IS - OCT
M1 - 1203
ER -
